Visual Outcome After Vitrectomy With Subretinal tPA Injection

Visual Outcome After Vitrectomy With Subretinal tPA Injection to Treat Submacular Hemorrhage Secondary to Age-related Macular Degeneration or Macroaneurysm

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05196139

Acronym

EVA-tPA

Enrollment

Registered

2022-01-19

Start date

2021-04-01

Completion date

2021-08-16

Last updated

2022-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Brief summary

evaluate the safety of Eva surgical system

Detailed description

The purpose of this retrospective study is to evaluate the safety and clinical results using this surgical technique when performed using the EVA surgical system and associated instrumentation and disposable surgical equipment

Interventions

OTHERretrospective study

vitrectomy performed in case of submacular bleeding

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* patients with VTX subretinal tPA ( + phaco) * patients with submacular bleeding

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
pre-operative best corrected visual acuity	pre surgery	• The pre-operative BCVA will be taken from the visit when the indication for the surgery was set
Surgical adverse events	postoperative visit on day 1	Surgical adverse events or issues that were recorded in the surgical report
post-operative best corrected visual acuity	6 weeks after surgery	The post-operative BCVA will be taken from the latest visit after the surgical procedure

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026